Ras inhibition enhances autophagy, which partially protects cells from death

Oncotarget

Volumn 4, Issue 1, 2013, Pages 145-155

  Schmukler, Eran ^a   Grinboim, Efrat ^a   Schokoroy, Sari ^a   Amir, Adva ^a   Wolfson, Eya ^a   Kloog, Yoel ^a   Pinkas Kramarski, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Autophagy; Ras; Signal transduction; Transformation

Indexed keywords

RAS PROTEIN; SALIRASIB;

ANIMAL CELL; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CELL PROTECTION; CELL STRAIN DLD 1; CELL STRAIN HCT116; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

EID: 84892853222     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Klionsky DJ and Emr SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000; 290(5497):1717-1721.
2. Wang C-W and J KD. The molecular mechanism of autophagy. Mol Med. 2003; 9:65-76.
3. Larsen KE and Sulzer D. Autophagy in neurons: a review. Histol Histopathol. 2002; 17(3):897-908.
4. Ogier-Denis E and Codogno P. Autophagy: a barrier or an adaptive response to cancer. Biochim Biophys Acta. 2003; 603:113-128.
5. Reggiori F and J KD. Autophagy in the eukaryotic cell. Eukaryot Cell. 2002; 1:11-21.
6. Chen Y and Klionsky DJ. The regulation of autophagy-unanswered questions. Journal of cell science. 2011; 124(Pt 2):161-170.
7. Wurmser AE and Emr SD. Phosphoinositide signaling and turnover: PtdIns(3)P, a regulator of membrane traffic, is transported to the vacuole and degraded by a process that requires lumenal vacuolar hydrolase activities. Embo J. 1998; 17(17):4930-4942.
8. Kihara A, Kabeya Y, Ohsumi Y and Yoshimori T. Beclinphosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Rep. 2001; 2(4):330-335.
9. Klionsky DJ. The molecular machinery of autophagy: unanswered questions. Journal of cell science. 2005; 118(Pt 1):7-18.
10. Vojtek AB and Der CJ. Increasing complexity of the Ras signaling pathway. The Journal of biological chemistry. 1998; 273(32):19925-19928.
11. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev. 1998; 8(1):49-54.
12. Harris AL, Nicholson S, Sainsbury R, Wright C and Farndon J. Epidermal growth factor receptor and other oncogenes as prognostic markers. J Natl Cancer Inst Monogr. 1992; (11):181-187.
13. Reddy EP, Reynolds RK, Santos E and Barbacid M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature. 1982; 300(5888):149-152.
14. Tabin CJ, Bradley SM, Bargmann CI, Weinberg RA, Papageorge AG, Scolnick EM, Dhar R, Lowy DR and Chang EH. Mechanism of activation of a human oncogene. Nature. 1982; 300(5888):143-149.
15. Vigil D, Cherfils J, Rossman KL and Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. Nat Rev Cancer. 2010; 10(12):842-857.
16. Lowy DR and Willumsen BM. Function and regulation of ras. Annual review of biochemistry. 1993; 62:851-891.
17. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A and Rosen N. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and-independent growth of human tumor cell lines. Cancer Res. 1995; 55(22):5302-5309.
18. Melisi D, Troiani T, Damiano V, Tortora G and Ciardiello F. Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. Endocr Relat Cancer. 2004; 11(1):51-68.
19. Shi Y, Hata A, Lo RS, Massague J and Pavletich NP. A structural basis for mutational inactivation of the tumour suppressor Smad4 [see comments]. Nature. 1997; 388(6637):87-93.
20. Aharonson Z, Gana-Weisz M, Varsano T, Haklai R, Marciano D and Kloog Y. Stringent structural requirements for anti-Ras activity of S-prenyl analogues. Biochim Biophys Acta. 1998; 1406(1):40-50.
21. Haklai R, Gana-Weisz G, Elad G, Paz A, Marciano D, Egozi Y, Ben Baruch G and Kloog Y. Dislodgment and accelerated degradation of Ras. Biochemistry. 1998; 37(5):1306-1314.
22. Elad G, Paz A, Haklai R, Marciano D, Cox A and Kloog Y. Targeting of K-Ras 4B by S-trans,transfarnesyl thiosalicylic acid. Biochim Biophys Acta. 1999; 1452(3):228-242.
23. Marom M, Haklai R, Ben-Baruch G, Marciano D, Egozi Y and Kloog Y. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J Biol Chem. 1995; 270(38):22263-22270.
24. McPherson RA, Conaway MC, Gregory CW, Yue W and Santen RJ. The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro. Prostate. 2004; 58(4):325-334.
25. Erlich S, Tal-Or P, Liebling R, Blum R, Karunagaran D, Kloog Y and Pinkas-Kramarski R. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem Pharmacol. 2006; 72(4):427-436.
26. Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I and Starkel P. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Mol Cancer. 2010; 9:256.
27. Weisz B, Giehl K, Gana-Weisz M, Egozi Y, Ben-Baruch G, Marciano D, Gierschik P and Kloog Y. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene. 1999; 18(16):2579-2588.
28. Halaschek-Wiener J, Wacheck V, Schlagbauer-Wadl H, Wolff K, Kloog Y and Jansen B. A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells. Mol Med. 2000; 6(8):693-704.
29. Halaschek-Wiener J, Wacheck V, Kloog Y and Jansen B. Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells. Cellular signalling. 2004; 16(11):1319-1327.
30. Zundelevich A, Elad-Sfadia G, Haklai R and Kloog Y. Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). Molecular cancer therapeutics. 2007; 6(6):1765-1773.
31. Mancias JD and Kimmelman AC. Targeting autophagy addiction in cancer. Oncotarget. 2011; 2(12):1302-1306.
32. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, Kamphorst JJ, Chen G, Lemons JM, Karantza V, Coller HA, Dipaola RS, Gelinas C, Rabinowitz JD and White E. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes & development. 2011; 25(5):460-470.
33. Kim MJ, Woo SJ, Yoon CH, Lee JS, An S, Choi YH, Hwang SG, Yoon G and Lee SJ. Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation. J Biol Chem. 2011; 286(15):12924-12932.
34. Mizushima N, Yamamoto A, Hatano M, Kobayashi Y, Kabeya Y, Suzuki K, Tokuhisa T, Ohsumi Y and Yoshimori T. Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. J Cell Biol. 2001; 152(4):657-668.
35. Bjorkoy G, Lamark T, Pankiv S, Overvatn A, Brech A and Johansen T. Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol. 2009; 452:181-197.
36. Liu EY and Ryan KM. Autophagy and cancer-issues we need to digest. Journal of cell science. 2012; 125(Pt 10):2349-2358.
37. Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, Bause A, Li Y, Stommel JM, Dell'antonio G, Mautner J, Tonon G, Haigis M, Shirihai OS, Doglioni C, Bardeesy N, et al. Pancreatic cancers require autophagy for tumor growth. Genes & development. 2011; 25(7):717-729.
38. Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen SM and Debnath J. Autophagy facilitates glycolysis during Rasmediated oncogenic transformation. Molecular biology of the cell. 2011; 22(2):165-178.
39. Elgendy M, Sheridan C, Brumatti G and Martin SJ. Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. Molecular cell. 2011; 42(1):23-35.
40. Byun JY, Yoon CH, An S, Park IC, Kang CM, Kim MJ and Lee SJ. The Rac1/MKK7/JNK pathway signals upregulation of Atg5 and subsequent autophagic cell death in response to oncogenic Ras. Carcinogenesis. 2009; 30(11):1880-1888